PL3505512T3 - Pochodne soli pirydyniowych jako prekursory do uwalniania MNA - Google Patents
Pochodne soli pirydyniowych jako prekursory do uwalniania MNAInfo
- Publication number
- PL3505512T3 PL3505512T3 PL18248109.3T PL18248109T PL3505512T3 PL 3505512 T3 PL3505512 T3 PL 3505512T3 PL 18248109 T PL18248109 T PL 18248109T PL 3505512 T3 PL3505512 T3 PL 3505512T3
- Authority
- PL
- Poland
- Prior art keywords
- derviatives
- mna
- nicotinamide
- precursors
- quaternary
- Prior art date
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 2
- 229960003966 nicotinamide Drugs 0.000 title 1
- 235000005152 nicotinamide Nutrition 0.000 title 1
- 239000011570 nicotinamide Substances 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL424073A PL238932B1 (pl) | 2017-12-31 | 2017-12-31 | Pochodne soli pirydyniowych oraz ich zastosowanie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3505512T3 true PL3505512T3 (pl) | 2022-07-25 |
Family
ID=65493778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL424073A PL238932B1 (pl) | 2017-12-31 | 2017-12-31 | Pochodne soli pirydyniowych oraz ich zastosowanie |
| PL18248109.3T PL3505512T3 (pl) | 2017-12-31 | 2018-12-28 | Pochodne soli pirydyniowych jako prekursory do uwalniania MNA |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL424073A PL238932B1 (pl) | 2017-12-31 | 2017-12-31 | Pochodne soli pirydyniowych oraz ich zastosowanie |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3505512B1 (pl) |
| PL (2) | PL238932B1 (pl) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB675430A (en) * | 1949-07-12 | 1952-07-09 | Cilag Ltd | Novel quaternary nicotinic acid amide derivatives and production thereof |
| PL364348A1 (pl) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego |
| US20110082177A1 (en) * | 2008-07-01 | 2011-04-07 | Jerzy Gebicki | N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases |
| JP6621329B2 (ja) * | 2012-10-05 | 2019-12-18 | スファエラ ファーマ ピーティーイー リミテッド | 新規化合物、それらの合成及びそれらの使用 |
-
2017
- 2017-12-31 PL PL424073A patent/PL238932B1/pl unknown
-
2018
- 2018-12-28 PL PL18248109.3T patent/PL3505512T3/pl unknown
- 2018-12-28 EP EP18248109.3A patent/EP3505512B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3505512A1 (en) | 2019-07-03 |
| PL238932B1 (pl) | 2021-10-18 |
| PL424073A1 (pl) | 2019-07-01 |
| EP3505512B1 (en) | 2022-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280485A (en) | Sustained-release pridopidine preparations | |
| GB2588505B (en) | Preparation of psilocybin | |
| PL3328867T3 (pl) | Krystaliczna postać wolnej zasady lorlatynibu | |
| HUE064651T2 (hu) | A bedaquilin késleltetett hatású formulái | |
| PL3474822T3 (pl) | Preparaty brincydofowiru | |
| IL268835B (en) | A process for the preparation of 2-cyanoimidazole compounds | |
| IL266683A (en) | Precursors for radiofluorination reactions | |
| SG11201803156TA (en) | Sustained release formulations of local anesthetics | |
| SMT202200202T1 (it) | Sali e polimorfi innovativi di scy-078 | |
| PL3110249T3 (pl) | Sposób wytwarzania mikrokapsułek biobójczych | |
| GB201609314D0 (en) | Methods of forming compounds | |
| IL263673A (en) | Solid state forms of spiro-oxindole compounds | |
| IL275480A (en) | A process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| IL271233A (en) | Quinolinicyclohexylpropanamide-modified compounds and improved methods for their preparation | |
| ZA201701063B (en) | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| IL248139A0 (en) | Preparation of microelectrodes | |
| PL3505512T3 (pl) | Pochodne soli pirydyniowych jako prekursory do uwalniania MNA | |
| PT3412667T (pt) | Cocristal | |
| IL263363A (en) | Polymorph of nintedanib | |
| GB201520346D0 (en) | Stable amorphous form of daclatasvir | |
| PT3393246T (pt) | Processo para a preparação de um agente quelante | |
| AU2015903141A0 (en) | Controlled release formulations of paracetamol | |
| HK1228789A1 (en) | Modified release formulations of pridopidine |